McKesson stock in focus after higher fiscal 2027 EPS outlook
AI-generated analysis
Key insights
๐ McKesson reported fiscal second-quarter revenue growth of 8% year over year, reaching $111.0 billion for the quarter ended September 30.
๐ฐ Adjusted diluted earnings per share surged 18% to $11.68, while GAAP diluted earnings per share rose to $10.44 from $8.92.
๐ต The company generated $3.1 billion in operating cash flow and $2.9 billion in free cash flow during the quarter.
๐ Management raised fiscal 2027 adjusted earnings guidance to a range of $45.60 to $46.40 per diluted share.
๐ The new guidance implies adjusted earnings growth of 17% to 19%, surpassing the long-term target range of 13% to 16%.
๐ฅ Growth was driven by North American Pharmaceutical, Oncology, Multispecialty, and Prescription Technology Solutions segments.
๐ Lower contributions from branded pharmaceuticals partially offset gains but did not hinder overall revenue expansion.
๐ณ๐ด The updated outlook includes effects from the Norway divestiture and net gains within The US Oncology Network in fiscal 2026.
๐ฎ Management expects fiscal 2027 revenue growth of 6% to 10% and adjusted operating profit growth of 12% to 16%.
๐ McKesson stock traded at 982.40 euros on Lang & Schwarz as of November 12, 2026.
๐ Bullish signals
๐McKesson reported a significant 8% year-over-year increase in fiscal second-quarter revenue, reaching $111.0 billion.
๐ฐAdjusted diluted earnings per share rose 18% to $11.68, demonstrating strong profitability growth.
๐ตThe company generated substantial cash flow with $3.1 billion in operating cash flow and $2.9 billion in free cash flow.
๐Management raised fiscal 2027 adjusted earnings guidance to $45.60-$46.40, expanding the previous range of $44.20-$45.00.
๐The updated guidance implies adjusted earnings growth of 17% to 19%, exceeding the long-term target range of 13% to 16%.
๐ฅGrowth was supported by higher prescription volumes and strong performance in Oncology, Multispecialty, and Prescription Technology Solutions segments.
Article
McKesson reported robust fiscal second-quarter results, with consolidated revenue rising 8% year over year to $111.0 billion for the quarter ended September 30. Adjusted diluted earnings per share increased significantly by 18% to $11.68, while GAAP diluted earnings per share climbed to $10.44 from $8.92 in the prior year.
The healthcare distributor generated strong cash flow metrics, producing $3.1 billion in operating cash flow and $2.9 billion in free cash flow during the period. Management attributed this operational progress to growth within North American Pharmaceutical, Oncology, Multispecialty, and Prescription Technology Solutions segments, supported by higher prescription volumes and specialty-product distribution.
Following these results, McKesson raised its fiscal 2027 adjusted earnings per diluted share guidance to a range of $45.60 to $46.40, up from the previous range of $44.20 to $45.00. This updated outlook implies adjusted earnings growth of 17% to 19% compared with the prior year, exceeding the company's long-term target range of 13% to 16% when excluding specific divestiture and network gain effects.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
McKesson (MCK) stock is currently trading at $785.43, which a valuation model suggests is undervalued by approximately 17.3% relative to a calculated fair value of $949.73. This assessment follows recent corporate developments including a US$2.25 billion senior secured term loan maturing in 2032, a minority sale within its Medical-Surgical Solutions division, and ongoing share repurchase programs.
Despite a recent pullback that has resulted in a 14.66% decline over the last 90 days and a 4.62% drop year-to-date, McKesson maintains a positive long-term track record with an 8.87% one-year total shareholder return and a substantial five-year history of rewards for investors. The company's strategy focuses on expanding value-added services such as pharmacy management and patient adherence solutions to build recurring revenue streams.
The bullish narrative relies on McKesson's ability to leverage its scale advantages in an increasingly complex pharmaceutical supply chain, which includes challenges like biosimilars and cold chain logistics. Analysts believe these factors contribute to competitive market share gains and margin expansion, though the stock faces potential headwinds from tighter drug price regulations and reduced reliance on wholesalers by vertically integrated payers.
๐ Stock trades at $785.43, a 17.3% discount to fair value of $949.73.
๐ฐ Secured US$2.25 billion senior loan maturing in 2032.
๐ Shares dropped 14.66% over 90 days and 4.62% year-to-date.
โ๏ธ P/E ratio of 19.3x is below industry average of 23.2x.
โ ๏ธ Risks include margin compression from drug price regulations.
๐ McKesson is currently trading at $785.43, representing a 17.3% discount to a calculated fair value of $949.73.
๐ฐ The company recently secured a US$2.25 billion senior secured term loan with a maturity date in 2032.
๐ Recent stock performance shows a 14.66% decline over the last 90 days and a 4.62% drop year-to-date.
๐ McKesson is actively executing share repurchases to support shareholder value despite recent market cooling.
๐ฅ The company sold a minority stake in its Medical-Surgical Solutions division as part of portfolio reshaping.
๐ Long-term holders have been rewarded with an 8.87% total return over the last year and strong five-year performance.
๐ ๏ธ McKesson is expanding value-added services including pharmacy management and patient access solutions to improve revenue visibility.
โ๏ธ Current P/E ratio of 19.3x is significantly lower than the US Healthcare industry average of 23.2x and peer average of 23.9x.
๐ฎ Valuation models assume McKesson will continue compounding scale advantages to drive steady top-line expansion.
โ ๏ธ Key risks include potential margin compression from tighter drug price regulations and payers reducing reliance on wholesalers.
Bullish Signals
McKesson trades at $785.43 vs $949.73 fair value, a 17.3% discount.
Secured US$2.25 billion term loan for growth without immediate dilution.
P/E ratio of 19.3x is below industry average of 23.2x.
8.87% one-year total shareholder return despite recent volatility.
Expansion into pharmacy management creates recurring revenue and margin visibility.
Risk Factors
Stock down 14.66% in 90 days and 4.62% YTD.
Margin pressure from potential tighter drug price regulations.
Payers/PBMs may reduce reliance on traditional wholesalers.
Bullish Signals
McKesson is trading at a significant discount with a fair value of $949.73 compared to the current price of $785.43, suggesting a 17.3% undervaluation.
The company has secured substantial financing via a US$2.25 billion term loan, providing capital for growth and operations without immediate dilution pressure.
Ongoing share repurchases demonstrate management's commitment to returning capital to shareholders and supporting the stock price.
McKesson holds a P/E ratio of 19.3x, which is well below the industry average of 23.2x and peer average of 23.9x, indicating a potential value opportunity.
The company's long-term track record remains strong with an 8.87% one-year total shareholder return despite recent short-term volatility.
Expansion into high-value services like pharmacy management and patient adherence solutions creates recurring revenue streams and improves margin visibility.
Risk Factors
Recent stock performance has been weak, with a 14.66% decline over the last 90 days and a 4.62% drop year-to-date.
The company faces potential margin pressure if tighter drug price regulations are implemented in the future.
There is a risk that vertically integrated payers and pharmacy benefit managers (PBMs) may reduce their reliance on traditional wholesalers like McKesson.
McKesson's cloud-based SupplyManager platform serves as a critical B2B e-commerce and inventory tool for thousands of U.S. hospitals, clinics, and physician practices. The web portal streamlines ordering workflows by providing a single interface to search the catalog, place orders, track shipments, and manage invoices, effectively replacing manual processes like phone calls and paper forms with standardized digital tasks.
The platform supports diverse user needs through features such as customized order templates, purchasing controls, reporting dashboards, and real-time product availability checks. It integrates with practice management and electronic health record systems to reduce data entry errors, while its browser-based access ensures usability for community practices without complex IT teams. McKesson emphasizes the system's reliability and resilience, treating it as a business-critical infrastructure supported by dedicated engineering roles focused on site reliability and hybrid cloud architectures.
Strategically, SupplyManager is central to McKesson's goal of being the primary channel for providers to source pharmaceuticals, vaccines, and medical-surgical products. By consolidating orders through its own portal, McKesson collects granular data on purchasing patterns and stock-outs, which aids in demand forecasting and strengthens customer relationships. The platform acts as a key touchpoint that keeps customers within the distributor's ecosystem, facilitating the integration of new services and supporting McKesson's broader technology and infrastructure strategy.
While McKesson does not separately report revenue for SupplyManager, grouping it within its distribution and technology offerings, the platform is viewed as vital for maintaining stickier customer relationships. As healthcare procurement continues to digitize, the portal's ability to provide visibility during supply chain stresses and support advanced analytics makes it a cornerstone of McKesson's operating model. The company's stock (MCK) reflects investor confidence in this growing technology footprint within its massive distribution scale.
๐ฆ Enables 24/7 online ordering for medical-surgical products and drugs.
๐ Integrates with EHR systems to reduce dual data entry.
๐ก๏ธ Uses hybrid cloud architecture to ensure minimal downtime.
๐ Standardizes buying behavior via customized order templates and controls.
๐ฐ Bundles contract pricing directly into the distribution relationship.
๐ฆ SupplyManager is McKesson's flagship B2B portal enabling 24/7 online ordering, real-time inventory checks, and invoice management for medical-surgical products and drugs.
๐ The platform integrates with practice management and electronic health record systems to reduce dual data entry and align ordering with internal item masters.
๐ก๏ธ McKesson employs dedicated software engineering roles focused on site reliability engineering and hybrid cloud architectures to ensure minimal downtime for thousands of daily users.
๐ Administrators utilize customized order templates, purchasing controls, and reporting dashboards to standardize buying behavior and monitor spending closely.
๐ The portal supports McKesson's strategy to be the primary sourcing channel, collecting granular data on purchasing patterns to improve demand forecasting.
๐ผ SupplyManager helps maintain customer stickiness by preventing volume fragmentation across competing channels or group purchasing portals.
๐ฅ It serves as a critical tool for navigating supply chain stresses, providing clear visibility into product availability and alternative items during shortages.
๐ Access is provided via web browser without requiring on-premise servers, making it accessible to community practices lacking complex IT teams.
๐ฐ The platform bundles contract pricing and real-time availability directly into the distribution relationship rather than selling as a standalone subscription.
Bullish Signals
Standardizes digital workflow to improve front-line care team efficiency.
Reduces dual data entry via seamless integration with internal item masters.
McKesson invests in dedicated engineering for strong incident management.
Granular purchasing data supports better demand forecasting and negotiations.
Portal visibility into product availability crucial during supply chain stresses.
Bullish Signals
SupplyManager transforms manual, error-prone ordering tasks into a standardized digital workflow, significantly improving efficiency for front-line care teams.
The platform's integration capabilities reduce dual data entry and make it easier for large health systems to align ordering with existing internal item masters.
McKesson's investment in dedicated engineering roles ensures the system is treated as business-critical with strong incident management and monitoring.
Consolidating orders through SupplyManager allows McKesson to collect granular data on purchasing patterns, supporting better demand forecasting and supplier negotiations.
The portal provides essential visibility into product availability and alternative items, which was crucial for providers during supply chain stresses like the pandemic.
A higher share of orders flowing through McKesson's own portal strengthens long-term customer relationships and facilitates the integration of new value-added services.
McKesson (MCK) recently reported a quarterly revenue shortfall that triggered a notable pullback in its stock price, though social media and analyst chatter highlight robust specialty distribution growth as a potential support factor. The company's shares are currently trading at what some observers describe as an attractive multiple relative to projected profits, suggesting a possible valuation opportunity despite the recent miss.
Insider activity has drawn significant attention, with executives including CEO Brian S. Tyler and EVP Michele Lau selling millions of dollars worth of shares over the past six months. While this aligns with typical post-earnings patterns, the lack of insider purchases raises questions about near-term confidence. Conversely, institutional investors show a mixed but active landscape, with major firms like T. Rowe Price reducing positions while others like Barclays and Goldman Sachs increased their holdings significantly.
Looking forward, McKesson is preparing for an upcoming Investor Day where users are tracking potential value creation from the planned medical-surgical separation and scaling of its specialty platform. Wall Street sentiment remains cautiously optimistic, with a median price target of $945 set by nine analysts in the last six months, ranging from $812 to $1,050, reflecting a neutral-to-positive outlook on execution risks in a competitive distribution landscape.
๐ Shares fell after revenue missed expectations.
๐ Analysts see specialty distribution driving growth.
๐ฐ Stock trades at attractive profit multiples.
๐ฆ T. Rowe Price cut holdings by 72.4%.
๐ฏ Median price target set at $945.
๐ McKesson shares pulled back following a quarterly revenue shortfall that missed expectations.
๐ Analysts highlight robust specialty distribution growth as a key driver for future earnings expansion.
๐ฐ The stock is currently trading at an attractive multiple relative to projected profits according to some observers.
๐ CEO Brian S. Tyler and other executives sold millions in shares over the past six months with zero purchases recorded.
๐ฆ Major institutional investors like T. Rowe Price reduced holdings by 72.4% while Barclays added 159.1% of its portfolio.
๐ Investors are tracking an upcoming Investor Day focused on the medical-surgical separation and specialty platform scaling.
๐ฏ Wall Street analysts have issued a median price target of $945 with targets ranging from $812 to $1,050.
๐ฅ Members of Congress showed net buying activity with three purchases against two sales in the last six months.
Bullish Signals
Q4 2026 revenues hit $96.3B, up 6.02%.
Robust specialty distribution growth supports future earnings.
Trading at attractive multiple relative to projected profits.
StockStory analysts have issued a mixed rating for S&P 500 stocks, recommending McKesson (MCK) as a buy while advising against Citizens Financial Group (CFG) and PulteGroup (PHM). The analysis highlights that while the S&P 500 offers stability, not all large-cap equities are performing equally, with specific concerns regarding slowing growth and profit pressure affecting CFG and PHM.
McKesson is identified as a potential positive return driver due to its status as one of the oldest continuously operating businesses in the US, founded in 1833. With a massive market capitalization of $88.61 billion, the healthcare services giant distributes pharmaceuticals and medical supplies while offering technology solutions to pharmacies and hospitals.
In contrast, Citizens Financial Group faces headwinds including muted revenue growth of 2.6% annually over the past two years and net interest income growth of only 5.8% over five years. The company trades at a forward price-to-book value of 1x, reflecting concerns about profitability where earnings per share growth trails revenue gains.
PulteGroup is flagged for avoidance due to its large scale limiting growth potential relative to smaller competitors, evidenced by below-average annual revenue increases of 1.2% over the last two years. Additionally, the homebuilder has seen earnings per share decline by 7.7% annually, and diminishing returns on capital suggest that previous profit drivers are losing momentum.
๐ Analysts recommend buying McKesson (MCK) for potential positive returns.
๐ Citizens Financial Group (CFG) advised against due to muted 2.6% revenue growth.
๐ PulteGroup (PHM) receives a sell rating with below-average 1.2% annual revenue increases.
๐ฐ McKesson market cap is $88.61 billion versus CFG's $25.55 billion and PHM's $21.52 billion.
๐ CFG trades at 1x forward price-to-book, indicating valuation concerns relative to peers.
๐ StockStory analysts recommend McKesson (MCK) as a buy within the S&P 500 for potential positive returns.
๐ Citizens Financial Group (CFG) is advised against due to muted 2.6% annual revenue growth and trailing earnings per share growth of 2.5%.
๐ PulteGroup (PHM) receives a sell rating as its large scale limits growth potential with below-average 1.2% annual revenue increases.
๐ฐ McKesson boasts a substantial market capitalization of $88.61 billion compared to CFG's $25.55 billion and PHM's $21.52 billion.
๐ CFG trades at a forward price-to-book value of 1x, indicating valuation concerns relative to its peers.
๐ PulteGroup faces declining earnings per share growth of 7.7% annually over the last two years.
๐ญ McKesson distributes pharmaceuticals and medical supplies while offering technology solutions to healthcare providers.
๐ The analysis focuses on S&P 500 performance outlook for the year 2026.
Bullish Signals
Established since 1833 with strong operational history.
Massive market cap of $88.61 billion indicates stability.
Offers diverse services in pharmaceutical distribution and logistics.
Risk Factors
CFG revenue growth slowed to 2.6% annually.
CFG net interest income growth lagged benchmarks.
PulteGroup large scale limits growth potential.
PulteGroup EPS declined 7.7% annually recently.
PulteGroup capital returns diminishing.
Bullish Signals
McKesson is highlighted as a stock with potential for good returns based on its long-standing operational history since 1833.
The company operates in the healthcare sector with a massive market capitalization of $88.61 billion, suggesting stability and scale.
McKesson provides diverse services including pharmaceutical distribution, medical supply logistics, and technology solutions to pharmacies and hospitals.
Risk Factors
Citizens Financial Group faces slowing growth with a muted 2.6% annual revenue growth rate over the past two years.
CFG's net interest income growth of 5.8% over the last five years fell short of typical banking sector benchmarks.
PulteGroup's large scale limits its growth potential relative to smaller competitors in the homebuilding industry.
PulteGroup has experienced a decline in earnings per share of 7.7% annually over the last two years.
Diminishing returns on capital at PulteGroup suggest that previous profit drivers are losing momentum.
McKesson Corporation reported a mixed first-quarter fiscal 2026 performance, characterized by a top-line revenue miss against analyst expectations despite year-over-year growth. The company posted revenue of approximately $96.3 billion, which represented roughly 6% growth but fell short of the consensus estimate of $101.6 billion. This shortfall was primarily attributed to softer sales in branded pharmaceuticals due to manufacturer price reductions and a sequential decline in GLP-1 prescription volumes.
Despite the revenue miss, McKesson delivered stronger-than-expected profitability metrics for the quarter. Adjusted earnings per share reached $11.69, beating the consensus forecast of $11.57 by about 1.1%, while adjusted EBITDA hit $1.92 billion, surpassing the $1.89 billion forecast. Operating margins remained stable at around 2.2%, reflecting management's focus on cost discipline and mix optimization within a high-volume, low-margin distribution business model.
Looking ahead to fiscal 2027, McKesson provided guidance projecting adjusted earnings per share with a midpoint of $44.20, which aligns broadly with current analyst expectations. The company continues to leverage its extensive logistics infrastructure and provider networks in oncology and specialty care to secure recurring revenue. Market data indicates the stock is trading near $759.82, below recent moving averages, as investors digest the divergence between volume-driven revenue challenges and margin stability.
The article highlights McKesson's role as a critical link in the US healthcare supply chain, connecting manufacturers with pharmacies and hospitals. Federal government contracts, such as a $36 million payment from the Department of Health and Human Services, contribute to its distribution volumes. For investors, the stock offers exposure to domestic prescription trends and pricing dynamics rather than direct drug development, making volume utilization and pricing shifts central themes for future performance.
๐ Q1 2026 revenue hit $96.3B, missing the $101.6B consensus by 5.3%.
๐ Sales miss caused by branded pharma price cuts and lower GLP-1 volumes.
๐ Adjusted EPS of $11.69 beat estimates, showing a 1.1% upside surprise.
๐ก๏ธ Operating margins stayed steady at 2.2% despite revenue decline.
๐ฅ Specialty therapeutics and oncology networks offset drops in commoditized categories.
๐ McKesson reported Q1 fiscal 2026 revenue of $96.3 billion, missing the $101.6 billion consensus estimate by approximately 5.3%.
๐ Revenue miss was driven by weaker branded pharmaceutical sales due to manufacturer price cuts and a sequential dip in GLP-1 prescription volumes.
๐ Adjusted EPS of $11.69 beat analyst expectations of $11.57, representing a 1.1% upside surprise.
๐ฐ Adjusted EBITDA reached $1.92 billion, exceeding the $1.89 billion forecast by roughly 1.7%.
๐ก๏ธ Operating margins held steady at around 2.2%, demonstrating effective cost control and mix optimization.
๐ฎ Fiscal 2027 guidance projects adjusted EPS with a midpoint of $44.20, aligning with market expectations.
๐ฅ Strong performance in specialty therapeutics and oncology provider networks offset declines in commoditized categories.
๐ต Stock traded near $759.82 on May 15, 2026, trading below mid-$850 moving averages.
๐ค Federal government contracts, including a $36 million HHS payment, support distribution volume stability.
๐ Company operates as a pure-play healthcare distributor without significant R&D revenue from drug development.
Bullish Signals
EPS of $11.69 beat consensus by 1.1%.
Adjusted EBITDA of $1.92B exceeded forecast.
Operating margins stable at 2.2%.
Fiscal 2027 EPS guidance set at $44.20.
Risk Factors
Revenue missed estimates by 5.3% at $96.3 billion.
Branded sales weakened due to manufacturer price cuts.
GLP-1 prescription volumes declined sequentially.
Stock trades below moving averages near $850.
Bullish Signals
Adjusted earnings per share of $11.69 exceeded analyst consensus of $11.57 by 1.1%, demonstrating strong operational profitability despite volume headwinds.
Adjusted EBITDA of $1.92 billion beat the $1.89 billion forecast, indicating effective cost management and margin preservation strategies.
Operating margins remained stable at approximately 2.2%, matching the prior-year quarter and highlighting disciplined expense control.
Robust activity in specialty pharmaceutical distribution and oncology networks provided a counterbalance to declines in branded pharma sales.
Fiscal 2027 EPS guidance of $44.20 aligns with analyst expectations, suggesting management confidence in maintaining earnings strength.
The company maintains a strategic advantage through its extensive logistics infrastructure and deep relationships with major pharmacy chains and health systems.
Risk Factors
Top-line revenue of $96.3 billion missed the consensus estimate of $101.6 billion by roughly 5.3%, indicating pressure on growth drivers.
Branded pharmaceutical sales weakened due to manufacturer price reductions, which directly impacted the top line and overall revenue growth.
GLP-1 prescription volumes experienced a sequential decline, reflecting potential headwinds in high-growth therapeutic categories.
The stock is trading below its 50-day and 200-day moving averages in the mid-$850 range, suggesting recent market skepticism or digestion of the revenue miss.
McKesson's (MCK) valuation outlook has become mixed as analysts diverge on its risk-reward profile following a reduction in Simply Wall St's fair value estimate from US$990.87 to US$951.73, representing a 4% decrease. This adjustment aligns with a shifting landscape where bullish banks like Bank of America lifted targets to US$1,040 and Barclays set US$1,050 in early 2026, citing upside potential from biosimilars such as the National Drug Code for Neulasta, while other firms including JPMorgan and Wells Fargo trimmed targets due to cautious valuation assumptions. William Blair initiated coverage with a bullish stance in April 2026, highlighting confidence in McKesson's execution within healthcare distribution, whereas Evercore ISI placed the stock on its "Tactical Underperform" list following an April target cut, signaling short-term concerns about execution risks that investors may weigh against long-term growth.
Financial and operational developments further define the current narrative, with McKesson repurchasing 2,500,000 shares between January 1, 2026, and March 31, 2026, for US$2.7 billion to reduce its outstanding share count by approximately 2.03%. The company also increased its total equity repurchase authorization to US$29 billion following a US$5 billion boost on April 29, 2026. Leadership transitions are underway as CFO Britt Vitalone retires after a two-decade career with plans for him to remain as a strategic advisor during the separation of the Medical Surgical Solutions business, while Kenny Cheung from Sysco assumes the CFO role effective May 29, 2026.
Simply Wall St updated its fair value model assumptions reflecting these broader market dynamics, adjusting revenue growth expectations down to 7.37% from 8.12%, slightly improving net profit margin forecasts to 1.21% from 1.19%, and lowering the future P/E multiple projection to 20.49x from 23.04x while raising the discount rate to 7.11%. The analysis underscores ongoing strategic narratives regarding expansion into specialty pharmaceuticals, oncology drugs, and value-added services that influence revenue mix, alongside investments in automation and digitization intended to drive long-term efficiency. Key risks remain centered on drug pricing pressure, vertical integration by manufacturers, margin compression from generic shifts, and evolving healthcare access technologies, as the stock continues to balance short-term tactical warnings with its broader long-term growth story in healthcare distribution.
๐ Fair value estimate reduced 4% due to lowered revenue growth assumptions.
โ๏ธ Analyst sentiment mixed with some raising targets while others cut them.
๐ฐ Repurchased $2.69B shares in Q1 2026; total authorization now $29B.
๐ CFO Britt Vitalone retiring; Kenny Cheung steps in as new CFO.
โ ๏ธ Risks include drug pricing pressure and manufacturer vertical integration threats.
๐ McKesson's fair value estimate was reduced from US$990.87 to US$951.73, representing a 4% decrease.
โ๏ธ Analyst sentiment is mixed, with some firms raising targets while others are cutting price targets or placing the stock underperform.
๐ Bank of America and Barclays increased their price targets in early 2026, citing upside from biosimilars and new business lines.
๐ William Blair initiated coverage with a bullish stance in April 2026, highlighting McKesson's strong execution in healthcare distribution.
๐ Several major analysts including Evercore ISI trimmed targets in April 2026 due to cautious assumptions on valuation and execution risk.
โ ๏ธ Evercore ISI specifically placed McKesson on its "Tactical Underperform" list focusing on short-term concerns.
๐ฐ McKesson repurchased 2.5 million shares worth US$2.69 billion between January and March 2026, totaling 43.79% of outstanding shares.
๐ The company increased equity repurchase authorization by US$5 billion, bringing the total approved to US$29 billion.
๐ CFO Britt Vitalone is retiring after 20 years and will transition to a strategic advisor role while Kenny Cheung steps in as new CFO.
๐ Revenue growth assumptions in the fair value model were lowered from 8.12% to 7.37%.
๐ผ Net profit margin assumptions were slightly improved from 1.19% to 1.21% in the updated valuation model.
๐ Future P/E multiple assumptions were reduced from 23.04x to 20.49x reflecting a shift in valuation outlook.
โ ๏ธ Discount rate assumptions were adjusted upward from 6.98% to 7.11% to reflect higher risk considerations.
๐ฌ Key long-term narratives include expansion into specialty pharmaceuticals and investments in automation and digitization.
๐ Investors face risks related to drug pricing pressure, vertical integration by manufacturers, and lower margin generics.
Bullish Signals
BofA/Barclays lifted targets to US$1,040/US$1,050 in early 2026.
Biosimilars like Neulasta offer upside with seven launching soon.
William Blair initiated bullish coverage in April 2026.
Repurchased 2.5M shares for US$2,695.61m Jan-Mar 2026.
Increased buyback authorization to US$29,000m on April 29, 2026.
Risk Factors
Fair value estimate trimmed 4% to US$951.73.
Revenue growth assumptions downgraded from 8.12% to 7.37%.
Future P/E multiple lowered from 23.04x to 20.49x.
BofA and Barclays both lifted their McKesson targets in early 2026, with BofA moving to US$1,040 and Barclays to US$1,050, signaling that some firms see room above the current fair value estimate.
BofA highlights potential upside from biosimilars, including McKesson's National Drug Code for a biosimilar version of Neulasta and the prospect of seven large biosimilars coming to market over the next few years.
William Blair initiated coverage with a bullish stance in April 2026, suggesting confidence in McKesson's execution and positioning within healthcare distribution and related services.
From January 1, 2026 to March 31, 2026, McKesson repurchased 2,500,000 shares for US$2,695.61m, demonstrating commitment to shareholder returns and confidence in its stock valuation.
On April 29, 2026, McKesson increased its equity repurchase authorization by US$5,000m, taking the total approved amount to US$29,000m, providing ample firepower for continued buybacks.
McKesson's net profit margin assumption improved slightly from 1.19% to 1.21%, indicating potential margin expansion despite revenue growth rate adjustments.
The transition to CFO Kenny Cheung brings experienced leadership with a background at Sysco, enhancing McKesson's capability in foodservice and distribution expertise.
Future P/E multiple remains elevated at 23.04x pre-adjustment, reflecting the market's recognition of McKesson's long-term earnings growth potential.
Risk Factors
Fair value estimate was trimmed by 4% from US$990.87 to US$951.73 in the latest model update, reflecting reduced analyst confidence.
Revenue growth assumptions were downgraded from 8.12% to 7.37%, indicating slower than previously expected expansion.
Future P/E multiple was lowered from 23.04x to 20.49x, suggesting a lower valuation premium relative to peers.
Multiple analysts including BofA, JPMorgan, Deutsche Bank, Baird, UBS, Wells Fargo and Evercore ISI have recently trimmed price targets, citing cautious assumptions around valuation or execution risk.
Evercore ISI specifically placed McKesson on a 'Tactical Underperform' list due to shorter term concerns investors may weigh against the long-term growth story.
The CFO Britt Vitalone is retiring after 20 years, creating a transition risk at Executive Vice President and CFO level with Kenny Cheung joining from Sysco effective May 29, 2026.
Key risks identified include drug pricing pressure, vertical integration by manufacturers and payers, lower margin generics, and shifts in healthcare access and technology.
McKesson Corp (NYSE:MCK) reported strong fiscal fourth-quarter results with full-year fiscal 2026 adjusted earnings per diluted share increasing by 18% to $39.11, driven primarily by growth in its oncology and multispecialty pharmaceutical segments. Consolidated revenue for the year reached $403 billion, up 12%, while operating cash flow of $6.2 billion exceeded company expectations. The quarter specifically saw adjusted earnings per diluted share rise 16% to $11.69 and revenue increase 6% to $96.3 billion, fueled by broad-based demand across specialty pharmaceutical distribution in North American Pharmaceutical and significant gains in oncology which rose 35% year-over-year.
Key highlights included substantial performance in the oncology sector where revenue grew to $12.7 billion and operating profit surged 53% to $385 million, largely supported by PRISM Vision and Core Ventures investments. Conversely, the Medical-Surgical Solutions segment faced headwinds from lower illness season demand for vaccines and testing, resulting in a flat year-over-year revenue and a slight decline in operating profit, though this impact was isolated to that specific division. GLP-1 distribution revenue also saw notable growth, reaching $14 billion in the quarter despite some sequential decline attributed to pricing factors that did not affect overall operating margins.
Looking ahead to fiscal 2027, McKesson issued guidance for adjusted earnings per diluted share between $43.80 and $44.60, implying year-over-year growth of 12% to 14%. Management reaffirmed its long-term target for earnings growth at 13% to 16%, with segment-specific outlooks projecting robust expansion in oncology and multispecialty lines between 14.5% and 18.5%. The company also outlined plans to return capital to shareholders through approximately $5 billion in share repurchases alongside free cash flow expectations of $4.5 billion to $4.9 billion for the next fiscal year.
Strategically, McKesson is advancing its separation plan for the Medical-Surgical Solutions division, aiming to spin it out as an independent company supported by new debt facilities totaling $2 billion and a strategic minority investment agreement with Apollo Funds for $1.25 billion. CEO Brian Tyler and CFO Britt Vitalone emphasized disciplined portfolio actions and operational momentum as the drivers behind the successful execution of fiscal 2026, positioning the company to maintain steady growth across its core business units despite external market challenges in pricing and specific product demand cycles.
๐ FY2026 revenue hit $403 billion with adjusted EPS growing 18% to $39.11.
๐ Specialty segments surged, including record $14B GLP-1 and 35% oncology growth.
๐ Company guided for $43.80โ$44.60 FY2027 EPS with a $1.25B Apollo investment in spin-off.
๐ McKesson reported strong full-year fiscal 2026 results with adjusted earnings per diluted share growing 18% to $39.11.
๐ฐ Fiscal 2026 consolidated revenue reached $403 billion, representing a 12% increase from the prior year.
๐ต Operating cash flow totaled $6.2 billion, exceeding company plans, while $5.1 billion was returned to shareholders.
๐ Fourth-quarter adjusted earnings per diluted share rose 16% year-over-year to $11.69 on revenue of $96.3 billion.
๐ Specialty pharmaceutical distribution in North American Pharmaceutical and oncology lines drove broad-based portfolio demand.
๐งฌ GLP-1 distribution revenue reached a record $14 billion in the quarter, up 22% year-over-year despite sequential decline.
๐ฅ Oncology and Multispecialty segment revenue surged 35% to $12.7 billion supported by provider growth and acquisitions.
๐ป Prescription Technology Solutions revenue grew 12% driven by higher volumes in third-party logistics and technology services.
โ๏ธ The company provided fiscal 2027 guidance for adjusted earnings per diluted share between $43.80 and $44.60.
๐ Management reaffirmed a long-term target for adjusted earnings per diluted share growth of 13% to 16%.
๐๏ธ McKesson plans to separate Medical-Surgical Solutions into an independent company with new debt facilities secured.
๐ค Apollo Funds agreed to a $1.25 billion strategic minority investment in the spin-off unit.
๐ธ Company expects free cash flow of approximately $4.5 billion to $4.9 billion for fiscal 2027.
๐ Management plans to repurchase approximately $5 billion of shares during fiscal 2027.
๐ Fiscal 2026 results included GAAP-only items including $480 million net gains from Norway divestiture and a $182 million LIFO credit.
McKesson Corporation (NYSE: MCK) reported quarterly results that beat analyst expectations for statutory earnings per share (EPS), which rose 9.0% above forecasts, though revenue came in roughly in line with estimates. Despite the positive earnings surprise, shares fell 8.9% to $736 in the week following the report, indicating some market disappointment or short-term volatility.
Following the earnings release, analyst consensus for fiscal year 2027 has been revised downward regarding revenue but upgraded significantly for profitability. The average forecast now predicts revenues of $431.7 billion and statutory EPS of $41.77, representing a 5.4% increase over the prior year. This shift suggests analysts are more bullish on McKesson's earnings power despite concerns that revenue growth may slow to an annualized 7.0% by the end of 2027.
The consensus price target remains stable at $959, with a valuation range spanning from $850 (bearish) to $1,065 (bullish). While McKesson's projected revenue growth is expected to decelerate compared to its historical 11% five-year average, it is still forecast to outpace the wider industry aggregate growth rate of 4.7%. Analysts maintain that earnings are more critical to intrinsic value than revenue figures alone.
๐ Shares fell 8.9% to $736 despite EPS beat.
๐ FY2027 revenue revised down to $431.7 billion.
๐ฐ Statutory EPS forecast upgraded to $41.77 for FY2027.
๐ฏ Average price target remains unchanged at $959.
๐ Analysts prioritize earnings power over revenue figures.
๐ Shares fell 8.9% to $736 despite a beat in statutory EPS, which was 9.0% higher than analyst expectations.
๐ Analyst consensus for FY2027 revenue is revised down to $431.7 billion, implying a 7.0% annualized growth rate through 2027.
๐ฐ Statutory EPS forecasts are upgraded to $41.77 for FY2027, representing a 5.4% increase over the previous year.
๐ฏ The average analyst price target remains unchanged at $959, with estimates ranging from $850 to $1,065.
๐ McKesson's projected revenue growth of 7.0% is expected to exceed the wider industry aggregate growth rate of 4.7%.
๐ Analysts have shifted sentiment toward earnings power, viewing it as more critical to intrinsic value than revenue figures.
Bullish Signals
Statutory EPS beat estimates by 9.0%.
FY2027 EPS forecast upgraded to $41.77.
Revenue growth projected at 7.0% annually through 2027.
Consensus price target remains stable at $959.
Risk Factors
Shares fell 8.9% after earnings report.
FY2027 revenue estimate downgraded to $431.7B.
Projected growth of 7.0% decelerates from 11% average.
Bullish Signals
McKesson beat analyst estimates for statutory EPS, with actual results coming in 9.0% higher than expected.
Analysts have upgraded their earnings per share forecasts for FY2027 to $41.77, indicating increased optimism about profitability.
The company is projected to grow revenue at 7.0% annually through 2027, which outpaces the wider industry average of 4.7%.
The consensus price target remains stable at $959, suggesting that intrinsic value has not materially changed despite recent market reaction.
Risk Factors
McKesson's shares fell 8.9% immediately following the earnings report, signaling short-term investor disappointment.
Analysts have downgraded revenue estimates for FY2027 to $431.7 billion, implying a slowdown in growth compared to historical rates.
Projected revenue growth of 7.0% represents a substantial deceleration from the company's historical five-year average of 11%.
McKesson Corporation delivered strong fourth-quarter financial results for fiscal 2026, reporting revenue of $96.3 billion, a 6% increase compared to the prior year, and adjusted earnings per share (EPS) of $11.69, up 16%. For the full fiscal year, revenue climbed 12% to $403.0 billion, while adjusted operating profit rose 15% to $6.5 billion and total EPS increased 18% to $39.11. Management highlighted that excluding one-time gains from McKesson Ventures, core underlying EPS growth was closer to 20%, driven by broad-based expansion in oncology, biopharma services, and supply chain improvements. The company generated significant cash flow with fiscal 2026 operating cash flow at $6.2 billion and free cash flow reaching $5.4 billion. Capital return initiatives included a total of $5.1 billion returned to shareholders through dividends and buybacks, with an accelerated repurchase of $2.25 billion in the fourth quarter; board approval was granted for an additional $5.0 billion in share repurchases, bringing total capacity to approximately $7.7 billion.
Growth was particularly robust in oncology and multispecialty operations, where fourth-quarter revenue jumped 35% to $12.7 billion and operating profit surged 53% to $385 million. This segment added over 570 providers in the quarter, representing its largest net increase since 2010, bolstered by acquisitions such as PRISM and Core Ventures. Biopharma services also scaled effectively, supporting a record 3.4 million patients across brand and specialty therapies, estimated to have saved customers roughly $10 billion on medication costs and prevented about 12 million prescription abandonments. The GLP-1 category remained a major growth driver with fourth-quarter distribution revenue rising 22% to $14 billion and full-year revenue increasing 27% to $53 billion, though management noted short-term volume volatility due to inventory adjustments.
To maintain efficiency and resilience, McKesson continued investing in automation and artificial intelligence, including a new Montreal distribution center with advanced storage technology that helped mitigate disruptions from a major winter storm. The company also advanced its strategy to separate the Medical-Surgical business, completing financing steps like a $1 billion term loan and revolving credit facility. Apollo Global Management invested $1.25 billion for a roughly 13% stake in the new entity, valuing it at approximately $13 billion, which provides liquidity for further share repurchases. However, executives noted headwinds such as branded pharmaceutical price declines that dragged down reported revenue by about 3% in the quarter and a sequential decline in GLP-1 volumes of 4%, advising investors to look through certain GAAP-only items like a $480 million gain from Norway divestiture and an $182 million LIFO credit to gauge underlying trends.
๐ Fiscal 2026 revenue grew 12% to $403B with adjusted profit up 15%.
๐ฐ EPS rose 18% to $39.11 driven by strong core operations.
๐ฌ Oncology surged 35% and GLP-1 revenues jumped 22% in Q4.
๐ฅ Automation investments improved efficiency while shareholder returns hit $5.1B.
๐ McKesson reported fiscal 2026 revenue growth of 12% to reach $403.0 billion with adjusted operating profit increasing 15% to $6.5 billion.
๐ฐ Adjusted earnings per share rose 18% year-over-year to $39.11, driven by strong core operations and excluding prior-year McKesson Ventures gains.
๐ The fourth quarter revenue increased 6% to $96.3 billion while adjusted EPS advanced 16% to $11.69 due to effective cost management.
๐ต Cash generation remained robust with fiscal 2026 operating cash flow of $6.2 billion and free cash flow of $5.4 billion.
๐ The company returned $5.1 billion to shareholders through buybacks and dividends, including a $2.25 billion accelerated repurchase in Q4.
โก Oncology revenue surged 35% in Q4 to $12.7 billion as the segment added over 570 providers, marking its largest net increase since 2010.
๐ฅ Biopharma services supported a record 3.4 million patients with productivity gains, enabling each employee to care for approximately 120 more patients than last year.
๐ GLP-1 distribution revenue jumped 22% in Q4 to $14 billion as the category continues to serve as a major growth driver.
๐ค Investments in automation and AI at new locations like the Montreal distribution center are driving working capital savings and supply chain resilience.
๐ The Medical-Surgical separation advanced with financing steps completed, including a $1.0 billion term loan and Apollo's $1.25 billion minority investment.
โ ๏ธ Branded pharmaceutical price declines negatively impacted reported revenue by cutting year-over-year growth by approximately 3% in the quarter.
๐ GLP-1 volumes showed quarterly volatility with a 4% sequential decline in Q4, which management attributed to inventory adjustments and supply patterns.
๐ฉน The Medical-Surgical Solutions segment posted modest Q4 revenue growth of 1% while operating profit decreased 5% to $271 million.
โ๏ธ Management cautioned investors to exclude GAAP-only items like a $480 million gain on the Norway divestiture when analyzing underlying trends.
๐ Operating expenses increased 14% in Q4 to $2.1 billion reflecting continued investments in strategic growth initiatives.
Bullish Signals
McKesson revenue grew 12% to $403B with adjusted profit rising 15%.
Adjusted EPS climbed 18% to $39.11, reflecting strong core operations.
Oncology segment Q4 revenue surged 35% with 570 new providers added.
GLP-1 full-year revenue increased 27% to record levels of $53B.
Biopharma services supported a record 3.4 million patients via productivity gains.
New Montreal AI distribution center saved working capital and prevented disruptions.
Risk Factors
Branded price cuts slashed reported revenue growth by ~3%.
GLP-1 revenue fell 4% sequentially due to supply issues.
Medical-Surgical operating profit dropped 5% to $271 million.
2027 guidance shows limited upside with flat-to-modest profits.
Separation faces risks from pending financing and regulatory approvals.
$480M gain and $182M LIFO credit distorted reported results.
Operating expenses rose 14% to $2.1B, hurting cost discipline.
Bullish Signals
McKesson delivered another year of double-digit growth with fiscal 2026 revenue climbing 12% to $403.0 billion and adjusted operating profit rising 15% to $6.5 billion.
Adjusted EPS increased 18% to $39.11, and management emphasized that underlying EPS growth was closer to 20%, underscoring the strength of core operations excluding one-time McKesson Ventures gains.
The fourth quarter capped the year on a solid note with revenue rising 6% to $96.3 billion and adjusted EPS advancing 16% to $11.69.
McKesson generated robust cash flow with fiscal 2026 operating cash flow of $6.2 billion and free cash flow of $5.4 billion, returning $5.1 billion to shareholders via buybacks and dividends.
Management secured Board approval for an additional $5.0 billion in share repurchases, bringing total repurchase capacity to roughly $7.7 billion.
Oncology and multispecialty operations were standout performers with Q4 revenue up 35% to $12.7 billion and operating profit surging 53% to $385 million.
The oncology segment added more than 570 providers in the quarter, its largest net increase since 2010, supported by strategic acquisitions like PRISM and Core Ventures.
GLP-1 revenues surged year over year with Q4 distribution revenue jumping 22% to $14 billion and full-year revenue increasing 27% to $53 billion.
Biopharma services delivered record annual verifications supporting a record 3.4 million patients, while productivity gains allowed each employee to support about 120 more patients than last year.
A new Montreal distribution center with advanced automation and AI-driven storage is already driving working capital savings and helping navigate disruptions like winter storms with minimal customer impact.
McKesson completed key financing steps for the Medical-Surgical separation, including a $1.0 billion term loan and $1.0 billion revolver, alongside a $1.25 billion minority investment from Apollo.
Risk Factors
Branded pharmaceutical price declines reduced reported revenue growth by approximately 3% in the quarter, weighing on overall top-line performance.
GLP-1 category revenue experienced a 4% sequential decline in Q4 due to supply patterns and inventory adjustments, introducing forecasting noise for investors.
The Medical-Surgical Solutions segment showed weak performance with Q4 operating profit down 5% to $271 million despite modest top-line growth of just 1%.
Fiscal 2027 guidance for the Medical-Surgical unit points to only low single-digit revenue growth and flat-to-modest profit gains, indicating limited upside potential.
The separation of the Medical-Surgical business depends on pending financing and regulatory approvals, adding significant execution risk to the strategic transition.
Reported results were distorted by nonrecurring items including a $480 million gain on the Norway divestiture, a $182 million LIFO credit, and other GAAP-only adjustments.
Operating expenses rose 14% in Q4 to $2.1 billion, raising questions about cost discipline relative to revenue growth.
McKesson (MCK) recently reported full-year fiscal 2026 results ending March 31, 2026, showing sales of US$403.43 billion and net income of US$4.76 billion, accompanied by higher earnings per share. Despite these solid operational results and a five-year total shareholder return of 296.55%, the stock has experienced recent weakness, falling 20.44% over 90 days and trading below analyst price targets with a one-day gain of only 1.49%. The article highlights a discrepancy between market sentiment and valuation models, where Simply Wall St's analysis pegs a fair value of $990.87 against the last closing price of $754.76, labeling the stock as undervalued based on future cash flows and projected revenue expansion.
The bullish narrative driving this higher fair value assumes McKesson will benefit from increasing supply chain complexity, including demands for biosimilars management, cold chain logistics, and personalized medicine, which favors large distributors over smaller competitors. This structural advantage is expected to drive top-line growth and margin expansion. However, the valuation relies on specific assumptions that could be tested by tighter drug pricing regulations or increased vertical integration by pharmaceutical manufacturers and payers, which might sideline traditional distribution models.
Financial metrics present a mixed picture regarding relative value; while McKesson trades at a forward P/E ratio of 21.3x, which is slightly above peer averages of 20.4x but below the analyst fair ratio estimate of 29.4x, this creates conflicting signals for investors. The stock appears as good value when compared to the broader US healthcare industry but looks more expensive than its closest peers, potentially leaving less room for error if market sentiment deteriorates. Consequently, investors must decide whether the long-term growth narrative justifies a premium over peer averages or if the current pullback represents a buying opportunity where the market is already pricing in future risks.
๐ McKesson achieved $403.43B sales and $4.76B net income for fiscal 2026.
๐ฏ Analyst fair value of $990.87 suggests current share price is undervalued.
โ ๏ธ Risks include tighter drug pricing regulations and manufacturer vertical integration.
๐ Analysis indicates temporary disfavor with potential for future upside.
๐ McKesson reported full-year fiscal 2026 results with US$403.43 billion in sales and US$4.76 billion in net income.
๐ Despite strong earnings, the stock price has declined over the last month (11.89%) and quarter (20.44%).
๐ค Long-term performance remains robust with a 5-year total shareholder return of 296.55%.
๐ฐ Analyst fair value targets at $990.87 suggest the current price of $754.76 may be undervalued.
๐ฌ The company is positioned to gain market share as pharmaceutical supply chains grow more complex.
โ ๏ธ Potential risks include tighter drug pricing regulations and vertical integration by manufacturers or payers.
๐ The stock trades at a P/E of 21.3x, which is above peer averages but below analyst fair ratio estimates.
โ๏ธ Valuation signals are mixed as the stock appears cheaper than the broader healthcare sector but pricier than peers.
๐ง Investors face a dilemma regarding whether to prioritize the peer premium or the gap to the fair value ratio.
๐ The analysis suggests McKesson could be temporarily out of favor and presents potential upside opportunities.
๐ก๏ธ Diversification is recommended through high-quality undervalued stocks, dividend aristocrats, and resilient low-risk companies.
โ ๏ธ This analysis relies on historical data and forecasts and does not constitute financial advice.
Bullish Signals
McKesson reported strong full-year results with sales of $403.43b.
Earnings grew year-over-year alongside improved margins and top-line expansion.
Five-year total shareholder return stands at an impressive 296.55%.
Analyst fair value suggests the stock is significantly undervalued.
P/E multiple of 21.3x indicates potential upside versus 29.4x estimate.
Risk Factors
Shares fell 11.89% in 30 days and 20.44% in 90 days.
Price of $754.76 trades below analyst targets despite bullish narratives.
Stricter drug pricing regulations could severely threaten profit margins.
Manufacturers may sideline distributors, risking market share erosion.
P/E of 21.3x exceeds peer average of 20.4x.
Bullish Signals
McKesson reported strong full-year results for the period ended March 31, 2026, with sales reaching US$403.43b and net income of US$4.76b.
The company demonstrated higher earnings per year-over-year growth alongside improved margins and top-line expansion.
Despite recent short-term volatility, the 5-year total shareholder return stands at an impressive 296.55%, highlighting strong long-term performance.
Analyst fair value calculations peg McKesson at $990.87, suggesting the stock is currently significantly undervalued compared to its last close of $754.76.
The business model benefits from increasing complexity in the pharmaceutical supply chain, which disproportionately favors large distributors like McKesson for competitive market share gains.
Current P/E multiple of 21.3x is slightly below the fair ratio estimate of 29.4x, indicating potential upside if sentiment corrects.
Risk Factors
McKesson's share price has declined significantly recently, with a 30-day decline of 11.89% and a 90-day decline of 20.44%, indicating immediate market pressure despite positive earnings.
The current stock price of $754.76 trades below analyst price targets, suggesting the market may already be incorporating near-term risks that contradict the bullish valuation narrative.
Regulatory concerns pose a threat to McKesson's profit margins if stricter drug pricing regulations are enacted in the coming years.
Competitive threats exist as vertical integration by manufacturers and payers could sideline traditional distributors like McKesson, potentially eroding its market share.
The stock trades at a P/E of 21.3x, which appears more expensive than its closest peers at 20.4x, creating less room for error if market sentiment turns negative.
While the fair value estimate of $990.87 suggests undervaluation, the divergence between this long-term target and current peer-relative pricing creates mixed signals on value.
The article notes that the analyst narrative relies on future cash flows assuming the business looks very different to today, introducing uncertainty if those transformative conditions do not materialize.
McKesson Corporation reported fourth-quarter fiscal 2026 adjusted earnings per share (EPS) of $11.69, surpassing the Zacks Consensus Estimate of $11.56 by 1.1% and showing a 15.5% year-over-year improvement in the bottom line. The enhanced EPS was primarily driven by strong operational performance across the business, including significant contributions from recent acquisitions within the Oncology & Multispecialty segment, while GAAP EPS rose to $13.71 compared to $10.01 in the prior year, boosted notably by a pre-tax credit related to the Rite Aid bankruptcy in the North American Pharmaceutical segment.
Despite beating on earnings, McKesson's revenue of $96.3 billion missed the Zacks Consensus Estimate by 5.5%, even though the top line grew 6% year over year. This growth was fueled by increased prescription volumes from retail national account customers and expansion in the distribution of oncology and specialty products, including contributions from acquisitions that bolstered the Oncology & Multispecialty segment, which saw revenues jump 31% to $12.71 billion and adjusted operating profit surge 53% to $385 million. Other segments showed more moderate growth; North American Pharmaceutical revenues increased 3% to $79.12 billion driven by specialty products, while Prescription Technology Solutions grew 12% to $1.5 billion and Medical-Surgical Solutions saw only a 1% increase to $2.87 billion.
The company highlighted margin expansion with adjusted gross profit reaching 4.01% of net revenues, an increase of nearly 28 basis points year over year, resulting in an adjusted operating income of $1.97 billion and an operating margin of 2.04%, up 15 basis points from the previous quarter. Cash and cash equivalents grew to $3.98 billion, reflecting cumulative net cash provided by operating activities of $6.16 billion, and McKesson reaffirmed its guidance for fiscal 2027, expecting adjusted EPS to improve 12-14% to between $43.80 and $44.60 alongside total revenue growth of 5-9%. The company also outlined specific segment projections, anticipating strong double-digit growth in Oncology and Multispecialty sales (14.5-18.5%) and significant profit improvements across all divisions, while noting the ongoing portfolio transformation toward a potential spin-off of the Medical-Surgical Solutions business expected by mid-2027.
๐ Q4 EPS beat estimates while revenue missed due to mixed segment performance.
๐ฐ Growth driven by oncology, technology solutions, and a Rite Aid credit.
๐ฅ Medical-Surgical Solutions business scheduled for spin-off in late 2027.
๐ McKesson reported Q4 adjusted EPS of $11.69, beating analyst estimates by 1.1% with a year-over-year bottom-line improvement of 15.5%.
๐ฐ The significant EPS growth was partially driven by a pre-tax credit related to the Rite Aid bankruptcy within the North American Pharmaceutical segment.
๐ Total revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%, despite a 6% year-over-year gain.
๐ฅ Revenue growth was primarily fueled by increased prescription volumes in retail national accounts and expansion in oncology and specialty product distribution.
๐ Lower contributions from branded pharmaceuticals partially offset the overall sales gains reported for the quarter.
๐ธ Adjusted gross profit reached $3.86 billion, representing a 14% year-over-year increase and an expanded margin of 4.01%.
โ๏ธ Operating income improved to $1.97 billion, marking a 14.6% rise from the prior-year quarter with operating margins expanding by nearly 15 basis points.
๐ After-hours trading saw shares fall 0.4% following mixed results where earnings beat but sales missed expectations.
๐ผ McKesson operates under four new reportable segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.
๐ The Oncology & Multispecialty segment saw revenue surge 31% to $12.71 billion, driven by provider solutions and recent acquisitions.
๐ฅ๏ธ Prescription Technology Solutions contributed significantly with revenues up 12% to $1.5 billion due to growth in logistics and technology services.
โ๏ธ Medical-Surgical Solutions revenues remained relatively flat at $2.87 billion, with gains from specialty drugs offset by lower ambulatory care contributions.
๐ค Management issued guidance for fiscal 2027, projecting adjusted EPS growth of 12-14% and total revenue growth between 5-9%.
๐ The company plans to complete the spin-off of its Medical-Surgical Solutions business in the second half of calendar 2027.
๐ McKesson completed the divestiture of its retail and distribution businesses in Norway, further shaping its global portfolio.
Bullish Signals
EPS beat estimates with $11.69 quarterly adjusted results.
GAAP EPS rose 15.5% year-over-year to $13.71.
Projected fiscal 2026 adjusted EPS climbs 18.3% to $39.11.
Revenues forecast reach $403.43 billion, a 12.4% increase.
Oncology & Multispecialty segment revenue and profit surged 31% and 53%.
North American Pharmaceutical adjusted operating profit grew 11%.
Prescription Technology Solutions revenues increased 12% on demand.
Full-year EPS guidance raised to $43.80-$44.60 range.
Cash equivalents strengthened from $2.96B to $3.98B.
Medical-Surgical Solutions revenue rose only 1% year-over-year.
Spin-off plan in 2027 may cause complexity or dilution.
Bullish Signals
McKesson reported fourth-quarter fiscal 2026 adjusted earnings per share (EPS) of $11.69, beating analyst estimates by 1.1%.
The bottom line improved significantly by 15.5% on a year-over-year basis to GAAP EPS of $13.71 versus $10.01 the prior year.
Fiscal 2026 adjusted EPS is projected to rise 18.3% to $39.11, demonstrating strong operational improvement across the business.
Revenues for fiscal 2026 are forecast to reach $403.43 billion, representing a robust 12.4% year-over-year growth.
The Oncology & Multispecialty segment delivered exceptional performance with revenues up 31% year over year and adjusted operating profit soaring 53%.
The North American Pharmaceutical segment saw adjusted operating profit increase by 11%, driven by growth in the distribution of specialty products.
Prescription Technology Solutions generated an uptick of 12% in revenues, fueled by increased demand for access solutions and third-party logistics services.
McKesson successfully raised its full-year guidance expectations, anticipating adjusted EPS to improve 12-14% to between $43.80 and $44.60.
The company's cash position strengthened materially with cash and cash equivalents increasing from $2.96 billion in Q3 to $3.98 billion at quarter-end.
Cash flow from operations remains highly robust, with cumulative net cash provided by operating activities totaling $6.16 billion compared to $6.09 billion the prior year.
The company expects Oncology and Multispecialty segment sales to grow rapidly at 14.5-18.5%, significantly outpacing other segments.
Risk Factors
McKesson's fourth-quarter revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%, despite earnings per share beating expectations.
The company failed to meet market expectations on sales, leading to a decline of 0.4% in after-hours trading on May 7, and shares are already down 9.7% year-to-date compared to the S&P 500's gain of 8.6% in the same period.
Lower contributions from branded pharmaceuticals partially offset revenue growth, indicating ongoing headwinds in traditional high-margin product categories.
The Medical-Surgical Solutions segment only saw a 1% year-over-year revenue increase and is facing lower contributions from the ambulatory care channel.
McKesson plans to complete the spin-off of its Medical-Surgical Solutions business in the second half of calendar 2027, which may introduce complexity or dilution concerns depending on execution.
Guidance for fiscal 2027 expects operating profit growth in the Prescription Technology Solutions segment to range from 11% to 15%, while the Medical-Surgical Solutions segment projects flat-to-up 4% operating profit growth, suggesting muted outlooks for key segments.
McKesson Corporation (MCK) reported fourth-quarter fiscal 2026 results on May 7, delivering an adjusted earnings per share (EPS) beat while missing revenue expectations. The company posted adjusted Q4 EPS of $11.69, surpassing the Zacks Consensus Estimate of $11.56 by 1.1%, with GAAP EPS reaching $13.71 due to a one-time pre-tax credit related to Rite Aid's bankruptcy in the North American Pharmaceutical segment. Full-year fiscal 2026 adjusted EPS guidance for fiscal 2027 reflects this improvement, with projected growth of 12-14% to a range of $43.80-$44.60.
Despite the earnings beat, Q4 revenues totaled $96.3 billion, falling short of analyst consensus by 5.5%, though this represented a 6% year-over-year increase driven primarily by retail national account customers and growth in oncology and specialty product distribution. The miss was partially attributed to lower contributions from branded pharmaceuticals. Operating margins expanded, with adjusted gross profit reaching $3.86 billion (4.01% of net revenues) and adjusted operating income rising 14.6% to $1.97 billion, driven by operational improvements across all business units.
Segment performance highlighted strong growth in the Oncology & Multispecialty division, which saw revenue jump 31% to $12.71 billion, fueled by provider solutions and acquisitions, while North American Pharmaceutical revenues grew 3% to $79.12 billion. Prescription Technology Solutions also contributed with a 12% revenue increase, whereas Medical-Surgical Solutions remained relatively flat at 1% growth. For fiscal 2027, McKesson expects total revenue growth of 5-9% and specific segment guidance ranging from 4% to 18.5% depending on the division, signaling continued confidence in specialty distribution and technology service demand despite the quarterly sales shortfall.
๐ฐ Adjusted EPS grew while revenue missed estimates slightly by 5.5%.
๐ Fiscal 2026 adjusted EPS forecast rises 18.3% to $39.11.
๐ฅ Oncology segment surged 31% driven by acquisitions and volume gains.
๐ฎ Guidance projects 12-14% adjusted EPS growth for fiscal 2027.
๐ MCK stock fell 0.4% in after-hours trading despite reporting a Q4 earnings beat, as shares lost 9.7% year-to-date while the broader market rose 8.6%.
๐ฐ Adjusted EPS of $11.69 exceeded analyst consensus by 1.1%, driven largely by a significant pre-tax credit related to the Rite Aid bankruptcy within the North American Pharmaceutical segment.
๐ GAAP EPS reached $13.71, representing a substantial improvement over the prior year's figure of $10.01.
๐ Full fiscal 2026 adjusted EPS is forecasted to rise 18.3% to $39.11, while GAAP EPS is projected to jump 49.2% to $38.38.
๐ธ Total revenue of $96.3 billion missed consensus estimates by 5.5%, though the top line still grew 6% year-over-year driven by retail national accounts and oncology growth.
๐ฅ The Oncology & Multispecialty segment was a standout with revenues surging 31% to $12.71 billion due to acquisitions and growth in provider solutions.
๐ North American Pharmaceutical segment revenue grew 3% to $79.12 billion, partially offset by lower branded pharmaceutical contributions but aided by increased prescription volumes.
๐ ๏ธ Prescription Technology Solutions revenues increased 12% to $1.5 billion, driven by higher demand for access and logistics services.
๐ฉน Medical-Surgical Solutions revenue remained flat at 1% growth ($2.87 billion), with profits up slightly due to cost optimization despite lower ambulatory care channel contributions.
๐ Adjusted operating margin expanded 15 basis points to 2.04%, supported by a 14% increase in adjusted gross profit.
๐ต Cash and cash equivalents grew to $3.98 billion, up from $2.96 billion in the previous quarter.
๐ Effective from Q2 of fiscal 2026, the company adopted new reportable segments including North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.
๐ฎ For fiscal 2027, McKesson expects adjusted EPS to grow 12-14% to a range of $43.80-$44.60 with total revenues growing between 5-9%.
๐ญ Future guidance specifies North American Pharmaceutical revenue growth of 4-8% and Oncology & Multispecialty revenue growth of 14.5-18.5%.
๐ค The company anticipates flat to +4% operating profit for the Medical-Surgical Solutions segment in fiscal 2027.
๐ Specialty distribution continued to be a key driver, supported by strong volumes and market share gains in community oncology.
McKesson Corporation (MCK) shares declined by 5.6% on May 6, 2026, driven primarily by negative sentiment spilling over from a major pharmaceutical distribution peer that recently reported an earnings miss and lowered its full-year outlook. The broader sector is currently under pressure as investors de-risk ahead of McKesson's scheduled fiscal 2026 fourth-quarter earnings report, which is set to be released after market close on May 7.
McKesson has reaffirmed its full-year fiscal 2026 outlook in its recent announcement, a move that leaves the stock more exposed to general sector-wide volatility rather than providing fresh company-specific positive updates. Analysts suggest this positioning may also reflect short-term technical adjustments following a strong prior run-up, with market focus shifting toward margin sensitivity inherent in large-scale drug distribution operations.
Institutional investor activity highlights significant divergence within the sector during Q4 2025. Major funds including UBS Asset Management and T. Rowe Price reduced their positions substantially, removing billions of dollars worth of shares, while others like Wellington Management also decreased holdings. Conversely, FMR LLC added to its position, indicating mixed institutional confidence in the immediate term.
๐ Stock dropped 5.6% on May 6 due to sector pressure.
๐ Q4 results report after market close on May 7.
๐ผ UBS cut holdings by $3.03 billion in Q4 2025.
๐ FMR added $227 million worth of shares in Q4.
๐ฏ Analysts maintain a median price target of $1,000.
๐ McKesson stock dropped 5.6% on May 6, 2026, following a peer's earnings miss and updated outlook that pressured the entire drug-distribution sector.
๐ The company is scheduled to report fiscal 2026 fourth-quarter results after market close on May 7, potentially amplifying pre-report volatility.
๐ McKesson reaffirmed its full-year fiscal 2026 outlook, leaving the stock exposed to broader sector moves rather than fresh positive updates.
๐ผ UBS Asset Management removed approximately $3.03 billion from its portfolio in Q4 2025, representing a 77.7% reduction in shares held.
๐ T. Rowe Price Investment Management reduced its position by 72.4%, selling roughly $950 million worth of shares in the same quarter.
๐ FMR LLC added 276,365 shares to its portfolio in Q4 2025, representing a 9.4% increase valued at approximately $227 million.
๐ฅ Insider trading data shows net selling over the past six months, with executives like Michele Lau and Napoleon Rutledge executing multiple sales totaling millions of dollars.
๐ฏ Wall Street analysts maintain a median price target of $1,000 for McKesson, with targets ranging from $885 to $1,107 across major firms.
โ๏ธ Congressional trading data reveals mixed activity, with members like Senator Markwayne Mullin making multiple purchases while others executed sales.
William Blair issued 'Outperform' rating on April 28, 2026.
JP Morgan target set at $1,107.
Risk Factors
Shares fell 5.6% on peer earnings miss and downgraded outlook.
Reaffirmed existing outlook leaves company vulnerable to sector volatility.
Institutional outflows saw UBS cut position by 77.7% in Q4.
Insiders sold shares in seven transactions with zero purchases.
Bullish Signals
McKesson has reaffirmed its full-year fiscal 2026 outlook, indicating management confidence in meeting previously set financial targets despite recent sector headwinds.
FMR LLC increased its position by 9.4% in Q4 2025, adding over $226 million to its holdings, suggesting continued institutional interest from major asset managers.
William Blair issued an 'Outperform' rating on April 28, 2026, signaling analyst confidence in the company's long-term prospects.
Multiple analysts have set price targets above current levels, with targets ranging up to $1,107 from JP Morgan and $1,050 from Barclays.
Risk Factors
McKesson shares fell 5.6% due to negative sentiment triggered by a major peer's earnings miss and downgraded full-year outlook.
The company reaffirmed its existing outlook rather than providing fresh positive updates, leaving it vulnerable to sector-wide volatility ahead of its May 7 earnings report.
Significant institutional outflows occurred in Q4 2025, with UBS Asset Management reducing its position by 77.7% and T. Rowe Price cutting holdings by 72.4%.
Insider trading data reveals a pattern of net selling over the past six months, with seven transactions recorded as sales and zero purchases among executives.
McKesson Corporation (MCK) is currently facing a challenging outlook despite its status as a fundamentally strong market leader in the healthcare distribution sector. The prevailing view characterizes the company's current valuation at over 21x P/E as unattractive, suggesting that significant upside potential is capped by mounting regulatory pressures, pricing constraints, and margin headwinds within the US healthcare landscape. A primary concern driving this cautious stance is the composition of McKesson's recent growth, which has been heavily reliant on high-priced drugs and revenue from GLP-1 medications; analysts warn that as these segments may plateau, underlying business vulnerabilities could become more exposed, limiting future expansion prospects.
Consequently, the consensus rating for McKesson at the time of this May 1, 2026, assessment is "Hold," with a specific price target set at $510 per share. This recommendation reflects an analysis that determines there is insufficient risk-to-reward balance to justify buying the stock at its current levels. The perspective emphasizes that while the company remains a dominant player, the combination of structural risks and valuation metrics makes it less appealing for immediate investment compared to other opportunities.
It is important to note that this analysis was provided by Wolf Report, an analyst who owns European and Scandinavian tickers directly rather than ADRs, as well as Canadian tickers for covered stocks. The content includes standard disclosures stating that the author does not hold positions in the mentioned companies, has no compensation relationships with them beyond Seeking Alpha's affiliate program, and explicitly clarifies that the opinions expressed do not constitute licensed financial advice. Investors are reminded to conduct their own due diligence and consult tax professionals regarding international withholding risks, as past performance is not indicative of future results.
๐ McKesson remains a strong market leader facing US healthcare structural risks.
๐ฐ Valuation is unattractive at 21x P/E with limited upside potential.
๐ค Wolf Report rates MCK 'Hold' with a $510 price target.
๐ McKesson (MCK) is described as a fundamentally strong, market-leading distributor of healthcare goods.
โ ๏ธ However, the company faces mounting structural risks within the US healthcare sector.
๐ฐ The current valuation is considered unattractive, trading at over 21x P/E.
๐ Upside is limited by potential regulatory headwinds, pricing pressures, and margin compression.
๐ A significant portion of recent growth comes from high-priced drugs and GLP-1 revenues which may plateau.
๐ Once the premium revenue streams stabilize, underlying business vulnerabilities could be exposed.
๐ค Wolf Report assigns MCK a 'Hold' rating with a price target of $510 per share.
๐ The analyst cites insufficient risk/reward potential at current market levels.
๐ The author previously reviewed MCK as too richly valued over the past two years.
๐ Wolf Report is a senior analyst and portfolio manager covering European and North American markets.
๐ค Members of Wolf of Value gain exclusive ideas, guidance, and direct access to the author via private chat.
โ ๏ธ The article includes standard financial disclosures stating the author is not a licensed financial advisor.
๐ซ Readers are advised to conduct their own due diligence before investing.
๐ Investing in European or non-US stocks carries specific withholding tax risks for investors.
Bullish Signals
McKesson Corporation is recognized as a fundamentally strong, market-leading distributor within the US healthcare sector.
The company benefits from current revenue streams driven by high-priced drugs and growing GLP-1 revenues.
Risk Factors
The stock's valuation is considered unattractive at over 21x P/E, suggesting a premium that limits upside potential.
Recent growth drivers like high-priced drugs and GLP-1 revenues are expected to plateau, exposing underlying business vulnerabilities.
McKesson faces mounting structural risks in the US healthcare sector, including regulatory and pricing pressures that threaten margins.
Analysts assign a 'Hold' rating with a $510/share price target, citing insufficient risk/reward at current levels.
The article highlights concerns about limited upside potential due to external sector headwinds despite strong fundamentals.
McKesson Corporation (MCK) is currently preparing to release its Q4 earnings report, with Wall Street analysts projecting an earnings per share (EPS) of $11.56 and revenue of $101.88 billion. Despite demonstrating strong growth over recent periods, the company's stock performance has lagged behind broader market trends, prompting questions regarding its future momentum. The article notes that McKesson operates within the Medical Distribution / Healthcare sector and has been in business since its founding in 1833.
McKesson provides healthcare services both in the United States and internationally through four primary segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions (RxTS), and Medical-Surgical Solutions (which was spun-off from the broader medical-surgical segment). The North American Pharmaceutical segment distributes various drugs and offers business solutions to pharmacies, while RxTS serves biopharma partners and provides technology solutions to connect patients with necessary medicines. The Oncology & Multispecialty segment focuses on oncology services, and the Medical-Surgical Solutions segment supplies healthcare providers ranging from physician offices to hospitals and home health agencies. The company is headquartered in Irving, Texas.
The broader market context during this period is described as "Fed week," where no interest rate movement is expected, though investors remain attentive to Federal Reserve comments on the global economy and domestic conditions. Oil prices are also under scrutiny due to price volatility linked to the war in Iran. As of the last update on April 28, 2026, major indices including the Dow Jones Industrial Average and S&P 500 have declined approximately 3% year to date, while the Nasdaq is down nearly 5%. The article also mentions that the company recently declared a quarterly dividend and highlights ongoing analyst focus on its valuation, earnings growth expectations, and insider trading sentiment.
The content includes various related headlines focusing on McKesson's trending status, dividend declarations, and comparative analyses with other medical stocks like Cardinal Health and Global Medical Products Holdings (GMDP). It also provides definitions for key financial metrics such as Fair Value, trailing total returns calculated against the S&P 500 benchmark, insider sentiment analysis, and hiring trends as indicators of company health. The text serves as an informational summary combining earnings previews, corporate segment overviews, and current market conditions surrounding McKesson's stock performance.
โ ๏ธ Market data currently shows temporary delays in stock quotes.
๐ Analysts forecast $11.56 EPS and $101.88B revenue for McKesson.
๐ข The company operates across four segments: Pharma, RxTS, Medical-Surgical, and International.
๐ Recent stock performance has lagged behind broader market trends.
๐๏ธ Current focus is on Fed decisions, interest rates, and global economic sentiment.
โ ๏ธ Market data on this page is currently experiencing temporary issues and showing delayed quotes.
๐ Analysts project McKesson (MCK) will report $11.56 EPS and $101.88 billion in revenue for its Q4 earnings report.
๐ผ The company operates across four segments including U.S. Pharmaceutical, RxTS, Medical-Surgical Solutions, and International divisions.
๐ Recent stock performance has lagged behind broader market trends despite the company demonstrating strong growth historically.
๐ McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
๐ฐ The U.S. Pharmaceutical segment distributes various drugs including branded, generic, specialty, biosimilar, and over-the-counter pharmaceuticals.
๐ค The RxTS segment connects patients with healthcare partners such as pharmacies, providers, and biopharma companies to improve medicine access.
๐ฅ Medical-Surgical Solutions offers supply distribution and services to hospitals, surgery centers, and long-term care facilities.
๐ The International segment delivers medicines and IT solutions to retail pharmacies, hospitals, and clinics outside the U.S.
๐ Year-to-date market performance shows significant losses across major indices including the Dow Jones, S&P 500, and Nasdaq.
๐๏ธ Current market focus includes interest rate expectations, global economic sentiments, and oil price fluctuations due to geopolitical tensions.
๐๏ธ This quarter is categorized as 'Fed week,' with investors closely monitoring Federal Reserve thoughts on the economy and global affairs.
Bullish Signals
McKesson Corporation is preparing for its Q4 earnings report with analysts projecting strong performance, estimating $11.56 in EPS and $101.88 billion in revenue.
The company operates through four robust segments: U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International, providing essential healthcare services globally.
McKesson has a long-standing heritage with roots dating back to 1833 and is headquartered in Irving, Texas, demonstrating stability in the medical distribution industry.
The company recently declared a quarterly dividend, indicating a commitment to returning value to its shareholders.
Risk Factors
Recent stock performance for McKesson (MCK) has lagged behind broader market trends, raising questions about future momentum.
The company operates through four segments including one being spun off (Medical-Surgical), which may introduce restructuring complexities or integration risks.
As part of 'Fed week,' the market faces uncertainty regarding interest rate movements and global economic conditions that could negatively impact investor sentiment.
Stocks are already down year-to-date (Dow and S&P 500 down 3%, Nasdaq almost 5%), creating a challenging environment for potential earnings-related rallies.
External geopolitical factors such as the war in Iran causing wide oil price swings may introduce cost inflation risks on McKesson's distribution margins.
McKesson Corporation (MCK) is anticipated to report earnings for the quarter ended March 2026 on May 7, with expectations of year-over-year growth in both revenue and earnings. The consensus forecasts project quarterly earnings per share (EPS) of $11.56, representing a 14.2% increase, while revenues are expected to reach $101.92 billion, up 12.2% from the prior year quarter. However, the consensus EPS estimate has been revised downward by 0.54% over the past 30 days, reflecting a shift toward bearish sentiment among analysts who are adjusting their predictions based on recent information.
The article utilizes Zacks Investment Research metrics to evaluate MCK's likelihood of beating these estimates. McKesson currently holds a Zacks Rank of #3 (Hold), but its Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in a negative Earnings ESP of -0.07%. According to Zacks' model, this combination makes it difficult to conclusively predict an earnings beat, although the company has a history of beating estimates over the last four quarters. The text warns that investors should not rely solely on EPS surprises when gauging stock price movement, as other business conditions and catalysts can also influence performance.
For context, the article compares MCK to peer Staar Surgical (STAA), another Zacks Medical - Dental Supplies industry company also set to report earnings in the upcoming period. Staar is expected to post EPS of $0.13 with revenues of $91.8 million for the quarter ended March 2026, figures that would represent significant year-over-year growth of 125% and 115.5% respectively. Like McKesson, Staar carries a negative Earnings ESP of -15.39% paired with a Zacks Rank of #3, making an earnings beat difficult to predict despite the company having beaten estimates in three of its last four quarters. Ultimately, while beating earnings expectations increases the odds of stock success, the article advises investors to consider multiple factors beyond just the EPS surprise when strategizing around upcoming quarterly releases.
๐ McKesson reports earnings on May 7 with projected EPS of $11.56 and revenue growth of 12.2%.
โ Consensus estimates dipped 0.54% recently, yielding a negative ESP that lowers beat probability.
๐ Staar Surgical shows mixed signals with a large negative ESP despite beating estimates historically.
๐ Use Zacks filters to navigate risks in these medical stocks before earnings releases.
๐ McKesson (MCK) stock is expected to fall more steeply than the broader market if it misses earnings expectations.
๐ The company is set to release its quarterly results for the period ended March 2026 on May 7.
๐ฐ Analysts project MCK will post quarterly earnings of $11.56 per share, reflecting a +14.2% year-over-year increase.
๐ต Revenue estimates stand at $101.92 billion, representing a 12.2% growth from the same quarter last year.
๐ The consensus EPS estimate has been revised downward by 0.54% over the past 30 days due to reassessed analyst projections.
๐ MCK currently carries a Zacks Rank of #3 (Hold) and an Earnings ESP of -0.07%, suggesting analysts have turned bearish.
โ ๏ธ A negative Earnings ESP reading combined with a Hold rank makes it difficult to predict that MCK will beat consensus EPS.
๐ In the last reported quarter, MCK delivered a +0.32% surprise by posting $9.34 per share against a $9.31 estimate.
๐ Over the past four quarters, MCK has beaten consensus EPS estimates on four separate occasions.
โ๏ธ Stock price movements are influenced by factors beyond earnings results, such as management discussion of business conditions.
๐ก The Zacks Earnings ESP model indicates that positive readings are strong predictors of beats but negative readings lack predictive confidence.
๐งช Staar Surgical (STAA) is another medical stock mentioned with expected EPS of $0.13 and revenues of $91.8 million.
๐ Staar Surgical shows a significantly lower Earnings ESP of -15.39% despite unchanged consensus estimates over the last 30 days.
๐ Staar Surgical has beaten consensus earnings three times over its last four reported quarters.
๐ Investors are encouraged to use the Zacks Earnings ESP Filter and Earnings Calendar for upcoming announcements.
๐ฐ The article notes that while betting on expected beats increases success odds, unforeseen catalysts can alter stock performance.
๐ Free analysis reports are available for both McKesson Corporation (MCK) and Staar Surgical Company (STAA).
๐ข Both companies belong to the Zacks Medical - Dental Supplies industry as categorized in the article.
Bullish Signals
McKesson projected +14.2% earnings and +12.2% revenue growth for March 2026.
Company beat EPS estimates for all four quarters in the last period.
Consensus EPS expectation stands at $11.56, representing significant year-over-year growth.
McKesson holds a Zacks Rank #3 associated with positive earnings surprises.
Risk Factors
McKesson (MCK) EPS estimate fell 0.54% due to analyst bearishness.
Negative Earnings ESP of -0.7% makes an earnings beat unlikely.
Zacks Rank #3 signals reduced likelihood of a positive surprise.
Analyst revision noise obscures the specific direction of individual updates.
Historical beats may fail as stock price drops regardless.
Significant downside risk exists ahead of May 7 report with $11.56 target.
Bullish Signals
McKesson is expected to deliver a year-over-year increase in earnings of +14.2% and revenue growth of 12.2% for the quarter ended March 2026.
The company has a strong historical track record, beating consensus EPS estimates for all four quarters in the last reported period.
Even with recent analyst estimate revisions, the consensus EPS expectation stands at $11.56 per share, representing significant growth over the prior year.
McKesson carries a Zacks Rank of #3 (Hold), which is associated with better predictive power for positive earnings surprises according to proprietary research.
Risk Factors
The consensus EPS estimate for McKesson was revised 0.54% lower over the last 30 days, reflecting analysts reassessing their initial estimates and growing bearishness.
McKesson's Most Accurate Estimate is lower than its Zacks Consensus Estimate, resulting in a negative Earnings ESP of -0.07%, which makes an earnings beat difficult to predict.
The company currently carries a Zacks Rank of #3 (Hold), but this combination with a negative Earnings ESP further reduces the likelihood of a positive surprise compared to Strong Buy or Buy ratings.
Investors face uncertainty as an aggregate change in estimates does not always reflect the specific direction of individual analyst revisions, adding noise to the outlook.
Historical performance shows that McKesson may disappoint even with beats; some stocks lose ground despite beating expectations due to other disappointing factors mentioned on management calls.
The article explicitly notes that McKesson does not appear a compelling earnings-beat candidate ahead of its May 7 report, suggesting significant downside risk if results deviate from the $11.56 per share expectation.
McKesson Corp. is experiencing a subtle shift in analyst valuations and narrative focus, particularly regarding its biosimilar pipeline and overall premium valuation. Most analysts maintain positive sentiment toward the stock despite minor fair value adjustments; Simply Wall St notes the model-based fair value has barely changed, dropping only slightly from $991.67 to $990.87. While the core valuation picture remains intact, there is a divergence in analyst price targets driven by specific strategic factors like execution on biosimilars and co-manufacturing options.
Institutional investors show mixed but generally supportive signals regarding McKesson's premium pricing relative to its three-year average. Benefactors Bank of America raised its target to $1,040 in March, citing value in the new National Drug Code for a Neulasta biosimilar and manufacturing optionality. Similarly, Barclays lifted its target to $1,050 in February, viewing the stock as a relative safe haven within healthcare, though it acknowledged the current valuation premium. Other firms including JPMorgan, Mizuho, Wells Fargo, TD Cowen, and Morgan Stanley raised targets in early February, while William Blair initiated bullish coverage. Conversely, Evercore ISI cut its target in April to place the stock on its Tactical Underperform list, and UBS and Bank of America lowered targets that month due to concerns over execution risks and share price premiums.
The article also highlights significant corporate governance and operational updates. Long-serving Executive Vice President and CFO Britt Vitalone plans to retire after a 20-year career but will transition to a strategic advisor role to support the separation of Medical Surgical Solutions and oversee the transition. Kenny Cheung is scheduled to join as the new CFO effective May 29, 2026, bringing extensive experience from Sysco in global financial planning, audit, tax, and corporate finance. Additionally, McKesson has been actively managing its share count through buybacks; between October 1, 2025, and December 31, 2025, the company repurchased 800,000 shares for $652.29 million, representing 0.65% of shares under a program launched in May 2018. Since the start of that program, the total repurchased is 64,000,000 shares or 41.75% of shares outstanding for $18.43 billion.
Financial modeling assumptions show minimal change, with the modeled revenue growth rate shifting slightly from 8.11% to 8.12%, net profit margin staying at 1.19%, future P/E assumption hovering near 23x, and the discount rate remaining essentially unchanged at 6.98%. The broader narrative emphasizes how specialty pharmaceuticals, oncology exposure, and acquisitions like Core Ventures and PRISM Vision are shaping revenue mix, alongside the company's focus on automation and digitization. Key risks identified include drug pricing pressure, industry consolidation, the growing use of lower-margin generics and biosimilars, and changing healthcare access dynamics impacting the core wholesale model.
๐ Bullish sentiment remains strong with multiple major firms raising price targets for the stock.
๐ผ CFO Britt Vitalone is retiring while Kenny Cheung joins as successor in 2026.
๐ฐ Company executed $652M share repurchases recently within a total of $18.4B buybacks since 2018.
๐ Some analysts lowered targets in April due to biosimilar risks and share premiums.
โ ๏ธ Key risks include drug pricing pressure, consolidation, and increasing generic/biosimilar margins.
๐ McKesson's fair value estimate shifted marginally from US$991.67 to US$990.87, indicating broadly intact core valuation despite model adjustments.
๐ผ BofA raised its price target to US$1,040 in March due to the potential value of McKesson's biosimilar pipeline and co-manufacturing optionality.
๐ Barclays lifted its target to US$1,050 in February, maintaining an Overweight rating while noting a premium to the three-year average.
๐ค Several major firms including JPMorgan, Mizuho, and Morgan Stanley raised price targets in early February, signaling support for higher valuation levels.
๐ William Blair initiated coverage with a bullish stance, reinforcing the positive broker sentiment surrounding the stock.
โฌ๏ธ Evercore ISI cut its target in April and placed McKesson on a Tactical Underperform list due to near-term risk and reward concerns.
๐ UBS and BofA also lowered price targets in April as investors weighed biosimilar execution risks and share price premiums.
๐ค Executive Vice President and CFO Britt Vitalone announced retirement after a 20-year career to transition into a strategic advisor role.
๐ผ Kenny Cheung is set to join McKesson as CFO effective May 29, 2026, bringing experience from Sysco in global financial planning.
๐ฐ Between October 1 and December 31, 2025, McKesson repurchased 800,000 shares for US$652.29 million as part of its buyback program.
๐ Since the start of its buyback program announced in May 2018, McKesson has repurchased 64 million shares (41.75% of total) for US$18.43 billion.
๐ The modeled revenue growth rate increased slightly from 8.11% to 8.12% in the latest fair value calculation.
๐ธ The projected net profit margin remains steady at 1.19%, and the future P/E assumption stayed nearly unchanged at around 23x.
โ ๏ธ Key risks highlighted include drug pricing pressure, industry consolidation, and the growing use of lower-margin generics and biosimilars.
๐ฅ Analysts are monitoring how specialty pharmaceuticals, oncology exposure, and acquisitions like Core Ventures shape McKesson's revenue mix.
Bullish Signals
JPMorgan and others raised targets signaling broad analyst support.
BofA lifted target to $1,040 highlighting biosimilar value.
Barclays raised target to $1,050 maintaining Overweight rating.
William Blair initiated coverage with a bullish stance.
McKesson repurchased 800,000 shares for $652.29m in Q4.
CFO Britt Vitalone transitioning to strategic advisor role.
Risk Factors
Competitive generics and biosimilars threaten core wholesale margins.
Industry consolidation risks traditional distribution business stability.
CFO retirement creates two years of leadership uncertainty.
Analysts lowered targets due to execution and valuation fears.
Stock premium leaves it vulnerable to market corrections.
Limited buyback impact keeps substantial float for volatility.
Bullish Signals
BofA increased its McKesson price target to US$1,040 in March, highlighting potential value in the biosimilar opportunity and co-manufacturing optionality.
Barclays lifted its target to US$1,050 in February and maintained an Overweight rating, viewing the company as a potential safe haven within healthcare.
Several major firms including JPMorgan, BofA, Mizuho, Wells Fargo, TD Cowen, and Morgan Stanley raised price targets in early February, signaling broad analyst support for higher valuation levels based on execution.
William Blair recently initiated coverage with a bullish stance, adding another positive voice to the group of supportive brokers around the stock.
McKesson repurchased 800,000 shares for US$652.29m between October 1, 2025 and December 31, 2025, representing 0.65% of shares under its buyback program.
Since the start of that buyback program announced on May 24, 2018, McKesson has repurchased 64,000,000 shares for a total of US$18.43b.
The modeled revenue growth rate has increased slightly from 8.11% to 8.12% in the latest fair value estimate.
Britt Vitalone is transitioning from Executive Vice President and CFO to a strategic advisor role after a 20-year career, specifically to support the planned separation of Medical Surgical Solutions and aid the transition.
Risk Factors
The company faces growing competitive threats from lower margin generics and biosimilars, which could erode its core wholesale margins.
Industry consolidation and changing healthcare access models pose significant risks to McKesson's traditional distribution business.
CFO Britt Vitalone is retiring after 20 years and will move into a strategic advisor role rather than remaining as an executive.
New CFO Kenny Cheung is not set to join until May 29, 2026, creating nearly two full years of potential leadership transition uncertainty during his interim period (noting the text implies he joins in 2026 which suggests a significant gap).
Several major analysts, including UBS and BofA, lowered their price targets in April due to concerns over biosimilar execution risks and the stock's existing valuation premium.
Evercore ISI cut its price target in April and downgraded McKesson to 'Tactical Underperform', citing near-term risk-reward concerns.
McKesson has maintained a significant premium to its three-year average, making it vulnerable if the market corrects or growth expectations slow.
Despite large buyback activity (US$652.29m in Q4 2025), the overall share count reduction over the program represents only 41.75% of issued shares, leaving a substantial float for potential volatility.
Gordon Reid, president and CEO of Goodreid Investment Counsel, highlighted McKesson Corp (NYSE:MCK) as a stable and attractive healthcare investment on BNN Bloomberg's Market Call on April 23, with the report updated on April 28, 2026. Reid emphasizes that GLP-1 drugs represent a significant growth opportunity for the company, noting its role as the world's largest pharmaceutical distributor that handles over one billion prescriptions annually. He attributes McKesson's long-term potential to favorable demographic trends and increasing drug volumes, describing the stock as predictable with consistent quality.
Reid further pointed out that the company is trading at an undemanding multiple relative to its growth prospects. Performance data indicates McKesson shares have gained 19.31% over the past 12 months and an impressive 342.2% over five years. Analyst sentiment remains largely positive, with 16 out of 18 analysts covering the stock rating it a "Buy," two rating it a "Hold," and none assigning a "Sell." The consensus price target for the stock is set at US$1,002.94.
The article also notes a discrepancy between the main financial reporting date and the biographical information provided for the author. While the news content refers to comments made in 2026, the byline details describe Rod Weatherbie as a journalist based in Prince Edward Island who has worked on Canadian property and casualty insurance since 2004 and contributed to various literary publications like The Fiddlehead. This suggests the article may be an older piece republished with updated metadata or a template insertion error regarding the author, as the financial data cited (such as the specific share gains and analyst counts) is presented within the context of a future date without clear explanation for the biographical mismatch.
๐ Top-tier stability backed by global dominance in one billion annual prescriptions.
๐ Major growth potential driven by GLP-1 demand and aging demographics.
๐ฏ High analyst consensus with 16 Buy ratings and a $1,002.94 price target.
๐ McKesson is described as an incredibly stable healthcare stock with long-term growth tied to pharmaceutical distribution demand.
๐ GLP-1 drugs represent a major growth area for the company according to investor Gordon Reid.
๐ McKesson is the world's largest pharmaceutical distributor, handling more than one billion prescriptions annually.
๐ต The company should benefit from aging demographics and rising drug volumes in the market.
๐ก๏ธ Investors appreciate McKesson for its consistency, quality, and reasonable valuation metrics.
๐ฐ Analysts rate the stock highly with 16 "Buy" ratings compared to two "Hold" ratings and zero "Sell" ratings.
๐ฏ The consensus price target from analysts covering the stock is US$1,002.94.
๐ McKesson shares have gained 19.31% over the past 12 months according to current data.
๐ Long-term performance shows significant growth with McKesson shares up 342.2% over five years.
๐ฒ The trading multiple is described as undemanding, suggesting a good value for investors.
Bullish Signals
McKesson is an incredibly stable healthcare name.
GLP-1 drugs offer significant upside potential for growth.
Handles over one billion prescriptions annually via distribution.
Shares gained 19.31% last year and 342.2% in five years.
Stock offers consistency with a reasonable undemanding multiple.
16 of 18 analysts rate the stock as 'Buy'.
Consensus price target is US$1,002.94 showing upside.
Risk Factors
Stock up 19.31% YTD may face correction if momentum slows.
Analysts expect strong growth leading to high valuation multiples.
Bullish Signals
McKesson is described as an incredibly stable healthcare name with long-term growth tied to pharmaceutical distribution demand.
GLP-1 drugs represent a huge growth area for McKesson, providing significant upside potential in this high-demand therapeutic class.
As the world's largest pharmaceutical distributor, McKesson handles more than one billion prescriptions annually, benefiting from aging demographics and rising drug volumes.
Shares have delivered strong momentum, gaining 19.31% over the past 12 months and an impressive 342.2% over five years.
The stock offers predictability, consistency, quality, and a reasonable valuation with an undemanding multiple.
Analyst sentiment is overwhelmingly positive, with 16 out of 18 analysts rating the stock as 'Buy' compared to none rated 'Sell'.
Investors have a consensus price target of US$1,002.94, suggesting significant upside from current levels.
Risk Factors
McKesson shares have already gained 19.31% over the past 12 months and 342.2% over five years, suggesting the stock is priced for significant further growth and may be vulnerable to correction if momentum slows.
The consensus price target of US$1,002.94 represents a significant upside from current levels, implying that many analysts expect continued strong performance which could lead to high valuation multiples.
McKesson Corporation (MCK) has experienced a recent share price pullback, with the stock closing at US$873.43 after declining 1.2% over seven days and 6.0% over 30 days. Despite these short-term drops, the company remains in a positive long-term trajectory, having delivered returns of 6.1% year to date, 29.1% over the past year, 143.1% over three years, and significantly higher gains over five years. This recent market movement occurs against a backdrop of sustained investor interest in large healthcare distributors, with focus remaining on how scale, operational efficiency, and supply chain capabilities influence long-term positioning amidst sector-wide cost pressures and ongoing policy discussions.
According to analysis by Simply Wall St, McKesson holds a value score of 4 out of 6 and appears potentially undervalued based on a Discounted Cash Flow model using a 2 Stage Free Cash Flow to Equity approach. Based on projected free cash flow estimates ranging from US$4.65 billion in 2026 to around US$7.17 billion by 2030, the model calculates an intrinsic value of approximately US$1,521.24 per share. This figure suggests the current trading price represents a discount of roughly 42.6% relative to the estimated fair value derived from future cash flow projections.
Valuation metrics also indicate the stock trades at a Price-to-Earnings ratio of 24.65x, which is higher than the broader Healthcare industry average of 22.60x but lower than the peer group average of 26.91x. Simply Wall St's proprietary Fair Ratio assessment places McKesson at 33.24x, suggesting the current P/E multiple remains below what their model implies should be supported by the company's growth profile and risk characteristics. The article concludes by emphasizing that investors may consider alternative narratives, such as varying analyst price targets ranging from US$860.00 to US$1,107.00, which reflect differing views on regulatory risks, consolidation dynamics, and potential efficiencies or biosimilar options, noting that these narratives help contextualize the gap between current market price and fair value estimates.
๐ Share price down 6% monthly but trades at 42.6% discount to DCF fair value.
๐ฐ P/E of 24.65x is below peer average while Free Cash Flow reaches $9.61B.
๐ McKesson (MCK) recently saw its share price drop 1.2% over seven days and 6.0% over the past month from a last close of $873.43.
๐ Despite the short-term pullback, the stock has returned 6.1% year-to-date, 29.1% over one year, 143.1% over three years, and significantly more over five years.
๐ก Sector interest remains high due to attention on scale, supply chain efficiency, and long-term positioning in healthcare distribution.
๐ A Discounted Cash Flow (DCF) model based on Free Cash Flow to Equity projects an intrinsic share value of $1,521.24.
๐ฐ This implies McKesson is trading at a 42.6% discount relative to the DCF model's estimated fair value.
๐ The P/E ratio stands at 24.65x, which is higher than the Healthcare industry average of 22.60x but lower than the peer group average of 26.91x.
๐ Simply Wall St calculates a proprietary Fair Ratio of 33.24x based on earnings growth and risk factors, suggesting current shares trade below that level.
๐ง Investors can evaluate valuation through "Narratives" linking analyst price targets (ranging from $860 to $1,107) with financial forecasts.
๐ Valuation approaches include adjusting for company-specific characteristics like biosimilar optionality and potential regulatory concerns.
โ ๏ธ The article is general commentary based on historical data and does not constitute financial advice or a recommendation to buy or sell.
๐ McKesson delivered annual Free Cash Flow of approximately $9.61 billion in the latest twelve months, with projected growth to $7.17 billion by 2030.
๐ฅ Continued investor focus is on which distributors are attractively priced given sector-wide cost pressures and policy discussions.
๐ Management's efficiency gains and supply chain capabilities continue to drive positive long-term positioning for the company.
Bullish Signals
P/E ratio at 24.65x is below Simply Wall St.
Risk Factors
Share price down 6% in last 30 days despite long-term gains.
P/E ratio of 24.65x exceeds industry average of 22.60x.
Analyst targets as low as $860 due to regulation and consolidation risks.
Valuation analysis may overlook recent announcements or material issues.
Bullish Signals
,.
,.
,.
s P/E ratio of 24.65x sits below Simply Wall St.
,.
,.
Risk Factors
McKesson's share price has declined over the last 30 days by 6.0%, indicating recent market weakness despite long-term gains.
The stock trades at a P/E ratio of 24.65x, which is above the broader Healthcare industry average of 22.60x and only slightly below its peer group average of 26.91x.
Some analyst price targets for McKesson sit as low as US$860.00, reflecting concerns around regulation and consolidation that could impact valuation.
The article notes that valuation analysis may not factor in the latest price-sensitive company announcements or qualitative material, creating a potential blind spot in investment assessment.
McKesson Corp. (MCK) shares gained 1.70% to close at $871.18 on Wednesday, marking a recovery after two consecutive days of declines. The stock's performance occurred during a broader favorable trading session for the market, as major indices recorded significant gains. The S&P 500 Index (SPX) rose 2.51% to reach 6,782.81, while the Dow Jones Industrial Average (DJIA) climbed 2.85% to close at 47,909.92. Despite the individual stock's upward movement on this particular day, the article notes that McKesson continues to underperform the overall market index.
The price increase was part of a larger trend where many stocks benefited from general market optimism. However, despite the recent rebound snapping its losing streak, McKesson remains categorized as an underperformer relative to the broader S&P 500 Index in terms of longer-term relative performance. The report does not specify new corporate developments or earnings data for McKesson, focusing primarily on the day's price action and market context.
The data for the article is provided by FactSet and MarketWatch Automation, with real-time quotes reflecting trades reported through Nasdaq. It is important to note that intraday data may be delayed at least 15 minutes or according to exchange requirements. The report is dated April 8, 2026, and reflects the status of U.S. stock quotes in local exchange time.
๐ MCK shares rose 1.70% to $871.18 amid broader market gains.
๐ S&P 500 gained 2.51% while Dow climbed 2.85% to record highs.
๐ McKesson Corp. (MCK) shares rose 1.70% to $871.18 on Wednesday amidst a favorable broader market session.
๐ The S&P 500 Index gained 2.51% to reach 6,782.81, while the Dow Jones Industrial Average climbed 2.85% to 47,909.92.
โ This price increase ended a two-day losing streak for the stock.
โ ๏ธ Despite the gain, McKesson still lags behind overall market performance in terms of relative strength.
Bullish Signals
McKesson stock rose 1.70% to $871.18 after a two-day losing streak.
S&P 500 rose 2.51% to 6,782.81; Dow rose 2.85% to 47,909.92.
Risk Factors
Stock underperformed S&P 500 and Dow by 1%.
Shares lost two straight sessions amid selling pressure.
McKesson shares rose only $871.18, missing broader rally.
Bullish Signals
McKesson Corp. stock rose 1.70% to $871.18, ending a two-day losing streak and demonstrating recent resilience despite underperforming the broader market.
Shares gained momentum in an all-around favorable trading session where the S&P 500 Index SPX rose 2.51% to 6,782.81 and the Dow Jones Industrial Average DJIA increased 2.85% to 47,909.92.
Risk Factors
McKesson Corp. stock continues to underperform the broader market, rising only 1.70% compared to the S&P 500's 2.51% and Dow Jones Industrial Average's 2.85% gains.
The company is experiencing a two-day losing streak, indicating recent selling pressure or negative sentiment.
McKesson shares are at $871.18, which represents a failure to capture the full rally of major market indices on this trading session.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)